An interventional study of Headache reprocessing and Headache education in Post-Traumatic Headache, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment
This study will test a new treatment, called Headache reprocessing, for persistent post-traumatic headache. The new treatment will be compared to a headache education intervention. The main objectives of the study are to examine the feasibility, safety, and clinical appropriateness of the new treatment.
Persistent post-traumatic headache (PPTH) is a common, debilitating health condition affecting Veterans and civilians. Relative to other headache disorders, PPTH is especially severe and impairing. PPTH has no established first-line treatments at this time. This research seeks to develop a new behavioral treatment, called headache reprocessing, to target fear and avoidance behaviors and cognitions, and associated neural changes, that drive PPTH. This trial will test the feasibility, safety, and clinical appropriateness of Headache Reprocessing Therapy by comparing it to a headache education control condition in a randomized controlled trial. We will randomize 60 Veterans with PPTH to take part in this study. Headache reprocessing and the educational control intervention will be delivered in group format over eight sessions (one per week for eight weeks). This intervention has the potential to improve available treatment options for PPTH.
192 studies on the registry are indexed under Post-Traumatic Headache; 54 are open to participants now.
This study's planned enrollment of 60 is above the median of 44 across 169 interventional studies indexed under Post-Traumatic Headache.
Browse Post-Traumatic Headache studies →VA Office of Research and Development is the lead sponsor of 1,771 studies on the registry; 392 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavior therapy focused on sensations and avoidance behaviors
Behavioral: Headache reprocessing
Education about ways to limit and manage headaches
Behavioral: Headache education
Behavior therapy focused on sensations and avoidance behaviors
Education about ways to limit and manage headaches
Enrollment rate
Number enrolled out of number approached
Time frame: Typically up to 3 months, from initial referral to decision to enroll or not
Attrition
% of randomized who are lost to follow-up before week 12
Time frame: 12 weeks
Attendance
Percent of participants attending 80+% of sessions
Time frame: During the 8-week intervention
Homework completion
Percent of participants completing 80+% of homework
Time frame: During the 8-week intervention
Credibility/Expectancy Questionnaire
Scale measuring how credible the intervention seemed to participants
Time frame: Week 12
Client Satisfaction Questionnaire
Scale measuring participant satisfaction with the intervention
Time frame: Week 12
Adverse events rated to the intervention
Adverse events determined to be caused by the intervention
Time frame: Full study period (28 weeks)
Change in Headache Impact Test-6 score
A widely-used scale measuring the impact that headaches have on daily life.
Time frame: Week 0 through Week 12
Plan to share: Yes — Final datasets in machine-readable format will be shared via PubMed Central
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Available upon study completion, indefinite
Access criteria: Public access
Data sharing details ↗ · pmc.ncbi.nlm.nih.gov
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →